Lipid nanoparticles for drug targeting to the brain.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Methods in Enzymology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/B978-0-12-391860-4.00012-4PMID 22449929
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blood-brain barrier genomics, proteomics, and new transporter discovery

  2011cited by this paper
• Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System

  2011cited by this paper
• Curcumin Entrapped Into Lipid Nanosystems Inhibits Neuroblastoma Cancer Cell Growth and Activates Hsp70 Protein

  2010cited by this paper
• Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution.

  2010cited by this paper
• Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases.

  2010cited by this paper
• Ferulic Acid-Loaded Lipid Nanostructures as Drug Delivery Systems for Alzheimers Disease: Preparation, Characterization and Cytotoxicity Studies

  2009cited by this paper
• Recent advances in medicinal chemistry and pharmaceutical technology--strategies for drug delivery to the brain.

  2009cited by this paper
• Lipid nanoparticles for parenteral delivery of actives.

  2009cited by this paper
• Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: Improved delivery by solid lipid nanoparticles

  2009cited by this paper
• Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells.

  2008cited by this paper
• Solid Lipid Nanoparticles Enhance the Delivery of the HIV Protease Inhibitor, Atazanavir, by a Human Brain Endothelial Cell Line

  2008cited by this paper
• Polymeric nanomedicine for cancer therapy

  2008cited by this paper
• The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?

  2008cited by this paper
• Potential of solid lipid nanoparticles in brain targeting.

  2008cited by this paper
• Active targeting schemes for nanoparticle systems in cancer therapeutics.

  2008cited by this paper
• Loading of curcumin into macrophages using lipid-based nanoparticles.

  2008cited by this paper
• Modelling of the blood–brain barrier in drug discovery and development

  2007cited by this paper
• Solid lipid nanoparticles for targeted brain drug delivery.

  2007cited by this paper
• Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells.

  2007cited by this paper
• Structure of the blood-brain barrier and its role in the transport of amino acids.

  2006cited by this paper
• Neurological disease in HIV-infected patients in the era of highly active antiretroviral treatment: a Brazilian experience.

  2006cited by this paper
• Mechanisms of neuronal injury and death in HIV-1 associated dementia.

  2006cited by this paper
• Improving the delivery of therapeutic agents to CNS neoplasms: a clinical review.

  2006cited by this paper
• Astrocyte–endothelial interactions at the blood–brain barrier

  2006cited by this paper
• Advances in strategies to improve drug delivery to brain tumors

  2006cited by this paper
• Impact of HIV on regional & cellular organisation of the brain.

  2006cited by this paper
• Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue?

  2006cited by this paper
• Drug delivery across the blood–brain barrier: why is it difficult? how to measure and improve it?

  2006cited by this paper
• Retracted: Notch‐1 down‐regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells

  2006cited by this paper
• Branched-Chain Amino Acids: Metabolism, Physiological Function, and Application

  2006cited by this paper
• A review of nanocarrier-based CNS delivery systems.

  2006cited by this paper
• Blood Compatibility of Cetyl Alcohol/Polysorbate-Based Nanoparticles

  2005cited by this paper
• The Blood-Brain Barrier/Neurovascular Unit in Health and Disease

  2005cited by this paper
• Intranasal drug delivery for brain targeting.

  2005cited by this paper
• Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?

  2005cited by this paper
• Targeted delivery across the blood–brain barrier

  2005cited by this paper
• Polyethylenimine-based non-viral gene delivery systems.

  2005cited by this paper
• Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro.

  2005cited by this paper
• Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.

  2005cited by this paper
• Enhanced Prospects for Drug Delivery and Brain Targeting by the Choroid Plexus–CSF Route

  2005cited by this paper
• Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns

  2005cited by this paper
• Diseases of the nervous system: patients’ aetiological beliefs

  2005cited by this paper
• Small molecule and monoclonal antibody therapies in neurooncology.

  2005cited by this paper
• Molecular biology of the blood-brain barrier

  2005cited by this paper
• Nanotechnology-based Drug Delivery for Cancer

  2005cited by this paper
• Molecular biology of the blood-brain barrier.

  2005cited by this paper
• Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26.

  2005cited by this paper
• Ferulic acid destabilizes preformed β-amyloid fibrils in vitro

  2005cited by this paper
• Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology.

  2004cited by this paper
• Efflux Mechanisms in the Central Nervous System: A Powerful Influence on Drug Distribution within the Brain

  2004cited by this paper
• Solid lipid nanoparticles for parenteral drug delivery.

  2004cited by this paper
• Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

  2004cited by this paper
• Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption.

  2004cited by this paper
• Drug delivery to the brain--realization by novel drug carriers.

  2004cited by this paper
• Drug transfer in the choroid plexus. Multiplicity and substrate specificities of transporters

  2004cited by this paper
• Novel delivery systems for drug targeting to the brain

  2004cited by this paper
• Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers

  2004cited by this paper
• In Situ Blood–Brain Barrier Transport of Nanoparticles

  2003cited by this paper
• Interactions of amphiphilic calix[4]arene-based Solid Lipid Nanoparticles with bovine serum albumin.

  2003cited by this paper
• Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: structure-activity studies.

  2002cited by this paper
• Radical scavenging activity and cytotoxicity of ferulic acid.

  2002cited by this paper
• Lipid-Drug-Conjugate (LDC) Nanoparticles as Novel Carrier System for the Hydrophilic Antitrypanosomal Drug Diminazenediaceturate

  2002cited by this paper
• Sir Richard Sykes contemplates the future of the pharma industry. Interview by Rebecca N Lawrence.

  2002cited by this paper
• Why is the global CNS pharmaceutical market so under-penetrated?

  2002cited by this paper
• Antioxidant properties of ferulic acid and its related compounds.

  2002cited by this paper
• Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

  2002cited by this paper
• Effects of Alcohol and HIV Infection on the Central Nervous System

  2001cited by this paper
• In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel.

  2001cited by this paper
• Protection against β‐amyloid peptide toxicity in vivo with long‐term administration of ferulic acid

  2001cited by this paper
• Brain drug targeting: Linker strategies: the engineering of multifunctional drug formulations

  2001cited by this paper
• Using Nanoparticles to Target Drugs to the Central Nervous System

  2000cited by this paper
• Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats.

  2000cited by this paper
• Protective Effects of Riluzole on Dopamine Neurons

  2000cited by this paper
• BMS-232632 : ANTI-HIV HIV-1 PROTEASE INHIBITOR

  1999cited by this paper
• Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration

  1999cited by this paper
• Natural Products: Anti‐inflammatory Activity in Rats and Mice of Phenolic Acids Isolated from Scrophularia frutescens

  1998cited by this paper
• A New Function for the LDL Receptor: Transcytosis of LDL across the Blood–Brain Barrier

  1997cited by this paper
• The Blood‐brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System

  1996cited by this paper
• Pharmaceutical characterization of commercially available intravenous fat emulsions: estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy.

  1995cited by this paper
• Camptothecins: from bench research to hospital wards.

  1994cited by this paper
• Evaluation of the antioxidant actions of ferulic acid and catechins.

  1993cited by this paper
• Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin.

  1991cited by this paper
• Determination of camptothecin in biological fluids using reversed-phase high-performance liquid chromatography with fluorescence detection.

  1990cited by this paper
• DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.

  1989cited by this paper
• Central nervous system dysfunction in acquired immunodeficiency syndrome.

  1988cited by this paper
• Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain.

  1987cited by this paper

• Lipid Nanocarriers as Precision Delivery Systems for Brain Tumors.

  2025cites this paper
• Nanoparticle targeting strategies for traumatic brain injury

  2024cites this paper
• Advancements in Ischemic Stroke Management: Transition from Traditional to Nanotechnological Approaches

  2024cites this paper
• COVID‐19 Vaccine mRNA Biodistribution: Maternal and Fetal Exposure Risks

  2024cites this paper
• Innovations in Breaking Barriers: Liposomes as Near-Perfect Drug Carriers in Ischemic Stroke Therapy

  2024cites this paper
• Strategies for the Management of Spike Protein-Related Pathology

  2023cites this paper
• Biodistribution of mRNA COVID-19 vaccines in human breast milk

  2023cites this paper
• A Historical Review of Brain Drug Delivery

  2022cites this paper
• A comprehensive update of siRNA delivery design strategies for targeted and effective gene silencing in gene therapy and other applications

  2022cites this paper
• Recent updates on applications of Lipid-based nanoparticles for site-specific drug delivery.

  2022cites this paper
• MiRNA10b-directed nanotherapy effectively targets brain metastases from breast cancer

  2021cites this paper
• Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier

  2021cites this paper
• Trends of Multimodal Neural Engineering Study: A Bibliometric Review

  2021cites this paper
• Solid Lipid Nanoparticles: Formulation and Applications in Food Bioactive Delivery

  2021cites this paper
• CARMUSTINE LOADED NANOSIZE LIPID VESICLES SHOWED PREFERENTIAL CYTOTOXICITY AND INTERNALIZATION IN U87MG CELL LINE ALONG WITH IMPROVED PHARMACOKINETIC PROFILE IN MICE: A STRATEGY FOR TREATMENT OF GLIOMA

  2020cites this paper
• Modern Approaches in Nanomedicine for NeuroAIDS and CNS Drug Delivery

  2020cites this paper
• Development and Optimization of Solid Lipid Nanoparticle Formulation for Enhanced Solubility of Ceritinib Using Box–Behnken Design

  2020cites this paper
• Therapeutic antisense oligonucleotides for movement disorders

  2020cites this paper
• Nanopharmaceuticals: Principles and Applications Vol. 3

  2020cites this paper
• Nanopharmaceuticals: Synthesis, Characterization, and Challenges

  2020cites this paper
• Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies.

  2020cites this paper
• Probing the drug delivery strategies in ischemic stroke therapy

  2020cites this paper
• Indinavir-Loaded Nanostructured Lipid Carriers to Brain Drug Delivery: Optimization, Characterization and Neuropharmacokinetic Evaluation.

  2019cites this paper
• Quantitative analysis of recombinant glucocerebrosidase brain delivery via lipid nanoparticles

  2018cites this paper
• Systematic approach for the formulation and optimization of atorvastatin loaded solid lipid NANOAPARTICLES using response surface methodology

  2018cites this paper
• Novel surface-engineered solid lipid nanoparticles of rosuvastatin calcium for low-density lipoprotein-receptor targeting: a Quality by Design-driven perspective.

  2017cites this paper
• Therapeutic Role and Drug Delivery Potential of Neuroinflammation as a Target in Neurodegenerative Disorders.

  2017cites this paper
• Sophorolipid Butyl Ester Diacetate Does Not Affect Macrophage Polarization but Enhances Astrocytic Glial Fibrillary Acidic Protein Expression at Micromolar Concentrations in Vitro.

  2017cites this paper
• Biocompatible Lipid Nanoparticles as Carriers To Improve Curcumin Efficacy in Ovarian Cancer Treatment.

  2017cites this paper
• Nanoparticulate strategies for the treatment of polyglutamine diseases by halting the protein aggregation process†

  2017cites this paper
• Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability

  2017cites this paper
• Mitochondria and neurodegenerative diseases: the promising role of nanotechnology in targeted drug delivery

  2017cites this paper
• Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches

  2017cites this paper
• Preparation and Characterization of Loperamide-Loaded Dynasan 114 Solid Lipid Nanoparticles for Increased Oral Absorption In the Treatment of Diarrhea

  2016cites this paper
• Nano-ART and NeuroAIDS

  2016cites this paper
• p-Aminophenyl-α-D-mannopyranoside engineered lipidic nanoparticles for effective delivery of docetaxel to brain.

  2015cites this paper
• Therapeutic applications of the cell-penetrating HIV-1 Tat peptide.

  2015cites this paper
• Blood-to-Brain Drug Delivery Using Nanocarriers

  2014cites this paper
• Nanoparticle formulation improves the anticonvulsant effect of clonazepam on the pentylenetetrazole-induced seizures: behavior and electroencephalogram.

  2014cites this paper
• Precision nanomedicine in neurodegenerative diseases.

  2014cites this paper
• The main challenge in the treatment of neurodegenerative diseases is to overcome the restrictive mechanism of the blood brain barrier and deliver therapeutic payloads to the brain . PERSPEC TIV E

  2014cites this paper
• Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA

  2013cites this paper
• Nanobiotechnology-based strategies for crossing the blood-brain barrier.

  2012cites this paper
• Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings

  2012cites this paper